The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1768
November 23, 2026
View Complete Issue         Table of Contents 2019 
Weltruza — A Once-Monthly Subcutaneous Formulation of Olanzapine
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Weltruza — A Once-Monthly Subcutaneous Formulation of Olanzapine
November 23, 2026 (Issue: 1768)
Weltruza (Teva), a once-monthly subcutaneous (SC) formulation of the second-generation antipsychotic drug olanzapine, has been approved by the FDA for treatment of schizophrenia in adults. A long-acting intramuscular (IM) formulation of...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Weltruza — A Once-Monthly Subcutaneous Formulation of Olanzapine
Article code: 1768b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.